export const PFIZER_CONVERSATION = [
    {
        id: 1,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "Good afternoon, Dr. Wilson. I'm Michael from Pfizer. Thanks for taking the time to meet with me today.",
    },
    {
        id: 2,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'Good afternoon, Michael. I’ve been curious about some of Pfizer’s latest treatments. What do you have for me today?',
    },
    {
        id: 3,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "Today, I’d like to talk to you about Ibrance, one of our key treatments for HR-positive, HER2-negative metastatic breast cancer. It's part of our CDK 4/6 inhibitor portfolio.",
    },
    {
        id: 4,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'I’ve heard of Ibrance. How does it fit into the current treatment landscape for metastatic breast cancer?',
    },
    {
        id: 5,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "Ibrance is indicated for use in combination with endocrine therapy, such as letrozole or fulvestrant, for HR-positive, HER2-negative advanced or metastatic breast cancer. It works by inhibiting the CDK4/6 proteins, which are key regulators of cell division, thus helping to slow the progression of the disease.",
    },
    {
        id: 6,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'And how effective has it been in clinical trials?',
    },
    {
        id: 7,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "The PALOMA-2 trial showed that Ibrance, when combined with letrozole, significantly improved progression-free survival compared to letrozole alone. The median progression-free survival was extended to 24.8 months versus 14.5 months with letrozole monotherapy.",
    },
    {
        id: 8,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'That’s impressive. What about the safety profile? Any concerns I should be aware of for my patients?',
    },
    {
        id: 9,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "Ibrance is generally well-tolerated, but neutropenia is the most common side effect, occurring in about 66% of patients. It’s manageable with dose adjustments or brief treatment interruptions. Other common side effects include fatigue, nausea, and infections.",
    },
    {
        id: 10,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'How should I be monitoring patients on Ibrance?',
    },
    {
        id: 11,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "Regular monitoring of blood counts is essential, particularly during the first two months of therapy. You'll also want to monitor for signs of infection, as neutropenia can increase the risk of infections. Additionally, dose reductions might be necessary if severe neutropenia occurs.",
    },
    {
        id: 12,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'Got it. Do you have any data on patient outcomes beyond clinical trials?',
    },
    {
        id: 13,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "Yes, we’ve collected real-world evidence from over 40,000 patients, which supports the clinical trial findings. Many patients have experienced prolonged disease control, with a manageable safety profile.",
    },
    {
        id: 14,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'That’s great to hear. And what kind of support does Pfizer offer for patients on Ibrance?',
    },
    {
        id: 15,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "Pfizer offers a range of patient support programs, including financial assistance and educational resources. We also have tools for you and your staff to help patients manage their treatment and stay adherent to their regimen.",
    },
    {
        id: 16,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'That’s helpful. What’s the dosing schedule like for Ibrance?',
    },
    {
        id: 17,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "Ibrance is taken orally, once daily, for 21 days followed by a 7-day break, in combination with letrozole or fulvestrant. Dose adjustments might be needed based on tolerability.",
    },
    {
        id: 18,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'Sounds straightforward. Thanks for all the information, Michael. I’ll definitely consider this for my patients.',
    },
    {
        id: 19,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: "Thank you, Dr. Wilson. I'll send over some additional materials and patient support information. Please don't hesitate to reach out if you have any more questions.",
    },
    {
        id: 20,
        speaker: {
            value: 'DrWilson',
            label: 'Dr. Wilson (Female)',
        },
        text: 'Will do. Have a good day, Michael.',
    },
    {
        id: 21,
        speaker: {
            value: 'Michael',
            label: 'Michael (Male)',
        },
        text: 'You too, Dr. Wilson.',
    },
];
